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Lentiviral Engineered Fibroblasts Expressing
Codon-Optimized COL7A1 Restore
Anchoring Fibrils in RDEB
Christos Georgiadis1,7, Farhatullah Syed1,7, Anastasia Petrova1, Alya Abdul-Wahab2, Su M. Lwin2,
Farzin Farzaneh4, Lucas Chan4, Sumera Ghani1, Roland A. Fleck3, Leanne Glover3, James R. McMillan5,
Mei Chen6, Adrian J. Thrasher1, John A. McGrath2, Wei-Li Di1,8 and Waseem Qasim1,8
Cells therapies, engineered to secrete replacement proteins, are being developed to ameliorate otherwise
debilitating diseases. Recessive dystrophic epidermolysis bullosa (RDEB) is caused by defects of type VII
collagen, a protein essential for anchoring fibril formation at the dermal-epidermal junction. Whereas allo-
geneic fibroblasts injected directly into the dermis can mediate transient disease modulation, autologous gene-
modified fibroblasts should evade immunological rejection and support sustained delivery of type VII collagen
at the dermal-epidermal junction. We demonstrate the feasibility of such an approach using a therapeutic
grade, self-inactivating-lentiviral vector, encoding codon-optimized COL7A1, to transduce RDEB fibroblasts
under conditions suitable for clinical application. Expression and secretion of type VII collagen was confirmed
with transduced cells exhibiting supranormal levels of protein expression, and ex vivo migration of fibroblasts
was restored in functional assays. Gene-modified RDEB fibroblasts also deposited type VII collagen at the
dermal-epidermal junction of human RDEB skin xenografts placed on NOD-scid IL2Rgammanull recipients, with
reconstruction of human epidermal structure and regeneration of anchoring fibrils at the dermal-epidermal
junction. Fibroblast-mediated restoration of protein and structural defects in this RDEB model strongly sup-
ports proposed therapeutic applications in man.
Journal of Investigative Dermatology (2016) 136, 284-292; doi:10.1038/JID.2015.364
INTRODUCTION
Recessive dystrophic epidermolysis bullosa (RDEB) is a
debilitating genodermatosis caused by loss-of-function mu-
tations in COL7A1 (Fine et al., 2014). Type VII collagen (C7)
is essential for anchoring fibril (AF) formation at the dermal-
epidermal junction (DEJ), and in RDEB, malformed,
reduced, or absent AFs are a direct consequence of COL7A1
mutations (Hovnanian et al., 1997). C7 is one of the main
contributors of dermal-epidermal adhesion, forming “wheat-
stack”-shaped, centrosymmetrically banded, semicircular
loop structures known as AFs after antiparallel dimerization
of two fibrils at their carboxyl (C)-termini (Burgeson et al.,
1990). These can be seen extending from their amino (N)-
termini that indirectly bind to hemidesmosomal a6b4 integ-
rin via the bridging activity of laminin-332 in the lamina
densa (Rousselle et al., 1997), where they protrude down to
the papillary dermis encircling dermal type I and III collagen
amongst other fibrous elements before terminating back in
the lamina densa (Shimizu et al., 1997). Loss-of-function
mutations in C7 lead to fragility of AF structures, thereby
compromising the integrity of the DEJ resulting in severe
sublamina densa blistering and tissue cleavage.
Clinically, skin blistering can follow even minor mechan-
ical stress causing skin erosions from birth in many subtypes
of RDEB. Moreover, chronic erosions with secondary in-
fections that can progress to widespread, mutilating scars and
joint contractures, and aggressive squamous cell carcinomas,
typify the severe generalized forms of RDEB (Fine and
Mellerio, 2009; Rodeck and Uitto, 2007). RDEB has a pro-
found medical and socioeconomic impact on patients and
their families (Tabolli et al., 2009). There are no curative
therapies for RDEB, and supportive care, with daily dressings,
meticulous wound care, nutritional support, and iron sup-
plementation for chronic anemia are the mainstay of clinical
management (Grocott et al., 2013; Mellerio et al., 2007).
Experimental therapies under development include re-
combinant C7 protein (Remington et al., 2008; Woodley
et al., 2004, 2013), infusion of allogeneic mesenchymal
cells (Conget et al., 2010), hematopoieticestem cell trans-
plantation (Tolar and Wagner, 2012; Wagner et al., 2010),
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and gene therapies (Droz-Georget Lathion et al., 2015;
Osborn et al., 2013; Sebastiano et al., 2014; Titeux et al.,
2010). We have investigated the feasibility of ex vivo gene-
modified cell-based delivery of C7 to restore AFs at the DEJ
of affected skin. Although both keratinocytes and fibroblasts
are involved in the production and secretion of C7, fibro-
blasts are generally more robust and easier to maintain in
culture, making them an attractive target for such an
approach (Goto et al., 2006). In addition, alternative ap-
proaches based on transduction of keratinocytes and pro-
duction of engineered skin grafts may not be suitable for
RDEB where the abnormal DEJ may compromise adhesion of
engineered epidermal sheets. In previous studies, intradermal
injections of allogeneic fibroblasts from healthy donors sup-
ported increased levels of COL7A1 expression in patients
with RDEB for several months (Nagy et al., 2011; Wong et al.,
2008). However, a recent phase II double-blind randomized
trial demonstrated the importance of intradermal control in-
jections. These comprised placebo (vehicle only) reagents
and resulted in similar levels of wound healing as with mis-
matched allogeneic fibroblasts (Venugopal et al., 2013). A
significant difference between injection of vehicle and allo-
geneic fibroblasts was only noted at day 7 (of 28 days) in a
separate trial (Petrof et al., 2013). Although the mechanism is
unclear, a localized anti-inflammatory effect and upregula-
tion of COL7A1 from intradermal inoculation of the vehicle
solution or injection needle itself (commonly used in scar
remodeling) has been postulated (Nagy et al., 2011; Petrof
et al., 2013; Venugopal et al., 2013). Irrespective of the
mechanism, a major limitation of allogeneic injections is the
immunological rejection of HLA-mismatched donor fibro-
blasts (Larcher and Del Rı´o, 2015; Venugopal et al., 2013;
Wong et al., 2008). An autologous approach using geneti-
cally modified RDEB fibroblasts should circumvent the risk of
rejection and provide a source of locally synthesized C7.
Previous reports have established the feasibility of modifying
fibroblasts with a variety of vectors, including phage (Ortiz-
Urda et al., 2003), gamma retrovirus (Goto et al., 2006;
Titeux et al., 2010; Woodley et al., 2007), and lentivirus
(Chen et al., 2002; Woodley et al., 2003), and local or sys-
temic injection into recipient mice has provided varying
degrees of evidence of restoration of skin integrity (Woodley
et al., 2004, 2007). We have developed a self-inactivating-
lentiviral (LV) platform combined with a human phospho-
glycerate kinase promoter and codon-optimized COL7A1 for
the engineering of autologous RDEB fibroblasts and have
shown definitive evidence of AF reconstruction at the DEJ in a
human:murine xenograft model. The production and valida-
tion of good-manufacturing-practice compliant reagents and
a robust process for manufacturing engineered fibroblasts
have enabled the submission of applications for regulatory
approval for first-in-man testing of this therapy.
RESULTS
Restoration of C7 expression in LV-COL7A1-transduced
RDEB primary fibroblasts
Primary fibroblasts from patients with RDEB lacking C7
expression were transduced with a third-generation
self-inactivating-LV vector encoding codon-optimized C7
(LV-COL7) under current good-manufacturing-practice
compliant conditions using a single round of exposure at a
multiplicity of infection 5 (Figure 1a). After 3 weeks of culture
and expansion, flow cytometric analysis showed 9.3e12.8%
of fibroblasts expressing C7 (Figure 1bed), and this
Figure 1. Expression of C7 in gene-corrected RDEB fibroblasts using a SIN-
LV-COL7A1 vector. (a) Configuration of pCCL-PGK-COL7A1 lentiviral
transfer plasmid shows a third-generation, split-packaging SIN vector with the
deleted U3 region of the 30LTR, internal PGK promoter, mutated woodchuck
hepatitis virus posttranscriptional regulatory element (WPRE), and central
polypurine tract (cPPT). Transgene COL7A1 was codon-optimized (co-
COL7A1) encoding the full-length COL7A1 sequence. (b, c) Average
expression of C7 in LV-COL7-transduced and untransduced (UT) primary
RDEB-1 and -2 fibroblasts by intracellular staining and flow cytometry with
corresponding mean fluorescence intensity (MFI) (d). (e) In situ expression of
C7 in RDEB-1 and -2 LV-COL7 fibroblasts using in-cell Western blotting
(ICWB). Green lanes represent C7 expression; red lanes represent loading
control (b-actin) expression with average immunoreactivity (f). LTR, long
terminal repeat; LV, lentiviral; PGK, phosphoglycerate kinase; RDEB,
recessive dystrophic epidermolysis bullosa; SD , standard deviation; SIN, self-
inactivating. Error bars represent SD of four replicates.
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corresponded to an integrated proviral copy number of
0.12e0.14 copies/cell. In-cell Western blotting showed
overexpression of C7 in transduced RDEB fibroblasts
compared with untransduced and wild-type (WT) fibroblasts
as measured by mean fluorescence intensity (Figure 1e and f).
In situ cytostaining also detected C7 protein expression in
transduced RDEB fibroblasts (Figure 2a), whereas there was
no expression in untransduced RDEB fibroblasts. These re-
sults were further confirmed by Western blot analysis using a
purified C7 antibody (a gift from Professor Mei Chen). Cell
lysates from transduced RDEB fibroblasts revealed the
expression of an approximately 290 kDa protein band cor-
responding to full-length C7 (Figure 2b) and expression was
stable when reassessed after 8 weeks. Full-length protein was
also detected in media harvested from cultured transduced
RDEB fibroblasts (Figure 2c) indicating effective secretion of
the recombinant protein. In view of previous reports that
around a quarter of gamma retroviral vector integrants,
particularly in keratinocytes, may encode truncated forms of
the COL7A1 transgene, we screened cultures for aberrant
protein forms, and found that only 3 of 49 single-cell clonal
populations expressed abnormally sized protein. This greatly
reduced frequency was attributed to our codon optimization
of the transgene, with residual low-level recombination
events during reverse transcription linked to a small number
of persisting repeat sequences.
Functional recovery in LV-COL7-transduced RDEB
fibroblasts
LV-COL7-transduced fibroblasts were assessed for viability
and metabolic activity using a water-soluble tetrazolium salt-
1 assay, with no differences observed compared with non-
corrected RDEB fibroblasts (Supplementary Figure S1 online).
In migration assays, the loss of C7 in RDEB cells has been
previously correlated with adverse functional effects on the
kinetics of wound closure compared with WT cells. Reports
have separately described both increased or decreased
migration associated with loss of C7, but with normalization
to WT levels after the reconstitution of C7 expression (Chen
et al., 2002; Martins et al., 2009; Nystrom et al., 2013).
Functional recovery in transduced RDEB fibroblasts was
examined by using a two-dimensional assay of fibroblast
migration across “wounds” created by cell-seeding stoppers
(Syed et al., 2013). RDEB fibroblasts had reduced (P < 0.05)
migration compared with WT fibroblasts, which was restored
by transduction with LV-COL7 (Figure 3a). The number of
cells within the 2 mm migration zone was analyzed using
ImageJ and revealed a significant increase in transduced
compared with nontransduced RDEB fibroblasts (P < 0.01),
with numbers similar to healthy donor fibroblasts (P > 0.05)
(Figure 3b).
Morphological correction of the DEJ in an RDEB
human:murine skin graft model
To determine whether secreted C7 produced from LV-COL7-
transduced fibroblasts can contribute toward the deposition
and incorporation of C7 into the DEJ in vivo, a modified
human:murine xenograft skin model was developed using
previously described procedures (Di et al., 2011, 2012;
Larcher et al., 2007). Primary RDEB fibroblasts were trans-
duced with LV-COL7 and seeded in a supporting fibrin matrix
composed of porcine plasma and human thrombin on which
primary keratinocytes were further seeded, generating a bio-
engineered skin graft. Control grafts carrying combinations of
primary healthy or untransduced RDEB keratinocytes and
fibroblasts were prepared alongside under the same condi-
tions. The bioengineered skin grafts were grafted onNOD-scid
IL2Rgammanull mice in duplicate for each condition and
allowed to mature over a period of 8 weeks. This provided an
opportunity to monitor two full cycles of human keratinocyte
and fibroblast development in vivo. At that point the grafts
were harvested and processed for cryosectioning and trans-
mission electron microscopy (TEM). Hematoxylin and eosin
staining showed distinct and fully differentiated human
epidermis with visible stratification and formation of a thick
cornified layer that was readily distinguishable from murine
tissue (Figure 4aec and Supplementary Figure S2aec online).
The human derivation of the grafted area was confirmed by
species-specific staining for human C7 and mitochondrial
markers (complex IV subunit II) and showed clearly demar-
cated human:murine borders (Figure 4def and gei). Human-
specific staining for desmoglein further verified the human
origin of the graft (Supplementary Figure S2dee online).
Epidermal proliferation and differentiation was confirmed by
staining of keratin 10 and involucrin in suprabasal layers and
the upper epidermal strata of terminally differentiated kerati-
nocytes, respectively (Figure 4jel and meo). Taken together,
these data support the adoption of a NOD-scid IL2Rgammanull
xenograft model for the reconstruction of human epidermal
structures pertinent to human RDEB modeling. Severe
blistering was observed in the RDEB grafts derived from
untransduced fibroblasts in combination with untransduced
keratinocytes and closely resembled the human disease
phenotype (Figure 4b). Tissue cleavage at the junction be-
tween basal keratinocytes and the underlying dermis resulted
in blister formation and epidermal sloughing uponmechanical
stress. On the contrary, there was no blistering observed using
the healthy donor fibroblast in combination with healthy
donor keratinocytes (Figure 4a). Importantly, in grafts
comprising vector-transduced RDEB fibroblasts with untrans-
duced keratinocytes, there was also no indication of blister
formation, consistent with restoration of theDEJ (Figure 4c and
Supplementary Figure S2aec) and supported by the detection
of C7 expression. Robust expression of human-specific C7was
seen only in grafts incorporating transduced fibroblasts, with
the deposition of the protein throughout the DEJ at levels
comparable with healthy donor grafts (Figure 5a and c). C7
expression could also be detected in fibroblasts in the dermis
by punctate staining in corrected RDEB grafts and healthy
donor grafts, but not in untransduced RDEB cell combinations
(Figure 5aec). Collectively, these data provide compelling
evidence that human C7 expression can be restored in vivo at
the DEJ by RDEB fibroblasts transduced with LV-COL7.
LV-COL7-mediated restoration of AFs at the DEJ of RDEB
skin grafts
To evaluate whether the C7 expression confirmed in grafts
incorporating LV-COL7-transduced RDEB fibroblasts
extended to the formation of AFs, ultrathin sections of each
graft were imaged by TEM. The micrographs revealed an
abundance sublamina densa fibrillary structures that bore the
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ultrastructural characteristics of normal AFs. These appeared
similar to the AFs seen in healthy donor control grafts,
exhibiting cross-banding and extending approximately 200
nm into the dermis, looping around type I and III dermal
collagen fibers (Figure 5d, h and f, i). The morphological
features of hemidesmosomes, subbasal dense plates, and
anchoring filaments also resembled control skin. In addition,
there was an abundance of plasmalemmal vesicles within the
finger-like protrusions of the basal keratinocytes in close
proximity to the basement membrane zone. In both control
and transduced grafts, there was no blistering or tissue
cleavage at the DEJ and a robust lamina densa throughout,
consistent with the functional correction of the DEJ with
restoration of dermal-epidermal adhesion by AFs (Figure 5d,
h and f, i). In contrast, the nonmodified RDEB grafts had a
blistering phenotype and an extensive splitting of sublamina
densa leading to complete separation of the epidermis from
the underlying dermis (Figure 5e and h). Moreover, the
hemidesmosomes were reduced in number, smaller and, in
some cases, internalized. There were no clearly discernible
AFs at the DEJ, in keeping with an absence of C7 by immu-
nofluorescent staining (Figure 5b). Overall, the data suggest
that C7 secreted by a modest proportion of engineered fi-
broblasts is sufficient for the generation of robust AFs and the
amelioration of blistering at the DEJ.
DISCUSSION
RDEB is a serious, painful, and disabling condition with
limited therapeutic options. Based on recent experience with
allogeneic fibroblasts (Wong et al., 2008), there is a strong
rationale to develop a therapy for RDEB using autologous
gene-engineered fibroblasts. Wong et al. reported allogeneic
fibroblast cell therapy for RDEB-supported twofold increases
in C7 immunostaining at the sites injected with donor fibro-
blasts, although it has been postulated that autocrine effects
exerted on recipient keratinocytes by inflammation-induced
heparin-binding EGF may also indirectly lead to increased
Figure 2. Restoration of full-length
C7 protein expression in RDEB
fibroblasts. (a) In situ
immunocytochemistry for type VII
collagen expression (C7) (red) and
nuclear stain 4’.6-diamidino-2-
phenylindole (blue) of either healthy
primary (WT) or RDEB-1 and -2
patient untransduced (UT) or LV-COL7
fibroblasts. C7 expression restored
after LV-COL7 transduction at MOI 5.
Bar ¼ 25 mm. (b) RDEB-1 and -2
fibroblast pellets were lysed before
assessment by SDS-PAGE. Restoration
of full-length C7 expression visualized
at 290 kDa in LV-COL7 and WT
fibroblasts. The complete absence of
C7 expression was seen in both RDEB-
1 and -2 UT samples. Vinculin
represents internal loading control. (c)
Culture supernatant from WT, RDEB-2
UT, and LV-COL7 fibroblasts showing
secreted C7 protein at 290 kDa after
lentiviral transduction. Ponceau S
used as internal loading control. LV,
lentiviral; MOI, multiplicity of
infection; RDEB, recessive dystrophic
epidermolysis bullosa; UT,
untransduced; WT, wild-type.
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synthesis and secretion of endogenous C7 (Nagy et al., 2011;
Wong et al., 2008). An unexpected indirect upregulation of
COL7A1was also found after intradermal injection of placebo
suspension solution alone (Nagy et al., 2011; Venugopal et al.,
2010), with further confirmation in a randomized clinical trial
(Venugopal et al., 2010), although the precise mechanism
remains unclear. In any case, such a therapy has potential
advantages over gene-modified epidermal graft approaches in
RDEB (Siprashvili et al., 2010), where there is concern that
grafts may fail because of the nature of the DEJ defects.
Localized injections of engineered fibroblasts could be used to
treat troublesome blistering lesions, and systemic delivery
may deliver more generalized benefit. The demonstration of
safety of vector-modified cells in a localized setting would
provide valuable data for subsequent systemic therapies using
the same vector platform.
Whereas allogeneic fibroblasts mediated only transient
benefits and were rejected over a matter of weeks, engi-
neered autologous cells should provide longer lasting effects.
This may be partly mediated through local effects triggered by
the intradermal injections, but more importantly by the
secretion of recombinant C7 produced in situ by a subpop-
ulation of transduced cells. Effective fibroblast transduction
has previously been reported using a variety of methods
(Chen et al., 2002; Ortiz-Urda et al., 2003; Woodley et al.,
2003) with a g-retroviral delivery developed with clinical
applications in mind, but troubled by low vector titer and
high frequency of abnormal, shortened collagen forms (Titeux
et al., 2010). Our LV platform was developed with clinical
applications in mind and includes a human phosphoglyc-
erate kinase internal promoter and co-COL7A1 transgene
with eliminated cryptic splice sites. All reagents, including
sera and enzymes, were sourced for their certificates of
analysis and transmissible spongiform encephalopathie
compliance. Vector titer was modest, reflecting the large
cargo size, and we found a greatly reduced frequency of
truncated, or variant, C7 forms arising because of recombi-
nation events during reverse transcription. Our data indicate
that ex vivo gene transfer to a modest number of fibroblasts
using this vector results in high levels of C7 expression at the
DEJ. The vector supports supranormal levels of protein
expression in transduced cells, as indicated by the high in-
tensities of C7 detected by Western blot, in-cell assays and
flow cytometry. Critically, the reconstitution of C7 at the DEJ
supported the regeneration of ultrastructural features
including AFs.
We found that the NOD-scid IL2Rgammanull immunode-
ficient mouse strain was amenable to human skin grafting
without the need for irradiation or additional immunosup-
pression. These animals are devoid of T, B, and NK cells with
additional defects of innate immunity and, thus, unable to
mount effective rejection of human xenografts. Previous
studies of human skin grafting (Di et al., 2011; Larcher et al.,
2007) adopted the Foxn1nu nude mouse strain, which is
athymic and deficient of T cells but can retain NK and other
aspects of the immune repertoire. Importantly, the grafts
recovered from our model had clearly demarcated human:-
murine junctional boundaries, and characteristic epidermal
structural features of healthy or RDEB skin, including a pre-
disposition for epidermal detachment and blistering.
Our experiments used ex vivo transduction and graft
preparation and were specifically designed to circumvent the
triggering of localized paracrine effects that may be induced
by injection into the epidermis. Whereas previous reports
suggested that residual or baseline expression of C7 by ker-
atinocytes may be necessary to secure a therapeutic effect
(Kern et al., 2009; Wagner et al., 2010; Wong et al., 2008),
we found that the restoration of C7 expression at the DEJ and
AF formation was mediated by transduced fibroblasts even in
combination with non-C7-expressing keratinocytes. This
translated to eradication of subepidermal cleavage seen in
noncorrected grafts.
With regard to future clinical translation, we have
completed the production and release of a clinical batch of
LV-COL7 and demonstrated engineering of human RDEB fi-
broblasts under good-manufacturing-practice conditions. UK
regulatory and ethics committee approval has recently been
secured for a first-in-man study, designed in the first instance
as a single-arm, open-label study to confirm the feasibility
and safety of an approach using the localized intradermal
injection of fibroblasts. If successful, comparison against
control injections will follow and further systemic therapies
Figure 3. Human RDEB fibroblasts
corrected for C7 showed improved
migration and “wound” closure
in vitro. (a) Representative
micrographs of RDEB-1 fibroblasts
corrected for C7 from three
independent experiments show the
migration pattern in a 2 mm migration
zone at 30 hours (T ¼ 30). (b) Bar
graph showing normalization of
migration of C7 corrected primary
RDEB-1 fibroblasts toward WT values
compared with uncorrected (UT)
primary RDEB fibroblasts at 30 hours.
Statistical analysis carried out using
Student’s t-test. C7, type VII collagen;
RDEB, recessive dystrophic
epidermolysis bullosa; SD, standard
deviation; WT, wild-type. Error bars
represent SD of four replicates.
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Figure 4. Visualization of human origin and epidermal cytoarchitecture of bioengineered skin sheets generated on NOD-scid IL2Rgammanull mice. (aec) H&E
staining of WT, RDEB-2 untransduced (UT), or LV-COL7 fibroblast (FB) graft combination seeded with WT or RDEB-2 UT patient keratinocytes (KC). Blistering
seen in RDEB-2 UT combination (stars). Bar ¼ 50 mm. Human-specific anti-C7 antibody showing expression in healthy and LV-COL7 grafts (d, f) but not in
untreated RDEB grafts (e). Bar ¼ 50 mm. (gei) Human-specific mitochondrial marker identifies the human:mouse junction: the border between mouse (ms) and
bioengineered human (hu) skin (dotted line). Bar ¼ 25 mm. Involucrin staining reveals cornification (jel); keratin 10 shows a later stage of KC differentiation
(meo). Epidermal-dermal tissue cleavage in RDEB-2 patient UT combination (dotted lines). C7, type VII collagen; H&E, hematoxylin and eosin; LV, lentiviral;
RDEB, recessive dystrophic epidermolysis bullosa; WT, wild-type. Bar ¼ 25 mm.
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will be envisaged using the same vector platform for the
treatment of RDEB and other debilitating skin diseases.
MATERIALS AND METHODS
RDEB skin biopsies and isolation and propagation of primary
fibroblasts
A 6-mm RDEB skin biopsy was obtained with authorization from the
National Research Ethics Services, Westminster (07/H0802/104),
and with written informed consent from patients with RDEB-1 ((þ/e)
c.1732C>T p.R578X)/(þ/e) c.2710þ2T>C IVS20þ2T.C) and RDEB-
2 ((þ/þ) c.425A>G p.K142R). Excess connective tissue was removed
using a sterile blade and the sample was incubated in neutral pro-
tease NB (1 unit/ml; SERVA Electrophoresis, Heidelberg, Germany)
at 37 C for 3 hours until the epidermis peeled off. The remaining
dermis was fragmented and treated with collagenase NB6 (0.45
units/ml; SERVA Electrophoresis). The resulting cell suspension was
seeded into a T25 flask and cultured at 37 C in a 5% CO2 incubator.
Production of third-generation COL7A1-expressing-LV
vectors with human phosphoglycerate kinase promoter
pCCL is a self-inactivating-LV vector (Figure 1a) derived from HIV-1
as described previously (Dull et al., 1998). Self-inactivation was
achieved through a 400 bp deletion in the 30HIV-1 long terminal
repeat and a 516 bp promoter sequence from human internal
phosphoglycerate kinase promoter was included as an internal
promoter (Ginn et al., 2010; Huston et al., 2011). A mutated
woodchuck hepatitis virus posttranscriptional regulatory element
sequence devoid of the hepadnaviral-X protein open reading frame
(WPREmut6) was cloned (Marangoni et al., 2009) downstream of a
full-length codon-optimized COL7A1 transgene (Geneart, Regens-
burg, Germany). The vector was pseudotyped with vesicular sto-
matitis virus glycoprotein using a split packaging system and
concentrated by ultracentrifugation. High-grade plasmids were
produced, characterized, and released (PlasmidFactory, Bielefeld,
Germany) for the production of good-manufacturing-practice vector
stocks.
Figure 5. In vivo functional correction through LV-COL7-mediated restoration of type VII collagen anchoring fibrils (AFs). C7 overexpression over WT (a)
visible in LV-COL7 RDEB-2 fibroblast (FB) containing graft (c), no protein deposition seen in untransduced (UT) graft (b). Bar ¼ 25 mm. TEM micrographs of WT
(d), RDEB-2 patient UT (e), and LV-COL7 (f) grafts. Bar ¼ 5 mm. (g) WT human keratinocyte (KC) and/or FB combination showing thick, cross-banded AFs
(arrows). (h) Loss of AFs causes extensive tissue cleavage at the dermal-epidermal junction (DEJ) of UT RDEB-2 KC and/or FB combination with lamina densa
(LD) reduplication. (i) UT RDEB-2 KC and/or LV-COL7 FB combination reveals restoration of dermal-epidermal adhesion. C, collagen type I and III; C7, type VII
collagen; HD, hemidesmosome; KF, keratin filament; LL, lamina lucida; LV, lentiviral; PV, plasmalemmal vesicle; RDEB, recessive dystrophic epidermolysis
bullosa; TEM, transmission electron microscopy; WT, wild-type. Bar ¼ 300 nm.
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Vector titer
The titer of concentrated LV-COL7 virus was determined by exposing
293 T cells with serial dilutions of concentrated LV-COL7. Three
days after transduction, cells were harvested and copies of HIV Psi
packaging element (J) were determined by quantitative polymerase
chain reaction. Proviral integrant copy number per transduced cell
was determined after normalization of J with housekeeping gene
albumin accounting for two albumin alleles per cell. Qualified
plasmid standards encodingJ and human albumin sequences were
used.
Bioengineered skin preparation and grafting on
immunodeficient mice
The methods for preparing and grafting bioengineered skin on
immunodeficient nude mice have been described previously
(Larcher et al., 2007). Our approach was similar, except the recip-
ient strain was NOD-scid IL2Rgammanull. In brief, fibrinogen solu-
tion (cryoprecipitate derived from a porcine plasma source)
containing 1.5 106 WT, RDEB-2 patient ((þ/þ) c.425A>G,
p.K142R) or RDEB-2 LV-COL7-transduced human dermal fibro-
blasts was combined with 0.025 mmol/l CaCl2 (Sigma-Aldrich,
Gillingham, UK) and 11 IU of bovine thrombin (Sigma-Aldrich). The
mixture was poured in two 35-mm wells and allowed to solidify at
37 C for 1 hour. WT or RDEB patient human keratinocytes (1.2 
106 cells per well) were then seeded on the fibrin matrix to form the
epidermal layer of the bioengineered skin. When confluent (3 days),
bioengineered skins were manually detached from tissue culture
wells and grafted onto immunodeficient mice. All animal pro-
cedures were performed in accordance with the United Kingdom
Animals Scientific Procedures Act (1986) and associated guidelines.
Grafting was performed under sterile conditions using 6-week-old
female immunodeficient mice (NOD-scid IL2Rgammanull) housed
under protective conditions. In brief, mice were aseptically
cleansed and anesthetized, and full-thickness 35-mm-diameter
circular wounds were then created on the dorsum of the mice.
Bioengineered equivalents were placed orthotopically on the
wound. The mouse skin removed to generate the wound was
devitalized by three repeated cycles of freezing and thawing and
used as a biological bandage and fixed with sutures to protect and
hold the skin substitute in place during the take process. Dead
mouse skin typically sloughed off within 15e20 days after grafting.
Eight weeks after grafting, bioengineered human skins were har-
vested postmortem preserving a surrounding border of mouse
epithelial tissue, snap frozen in LN2, embedded in optimum cutting
temperature (Sakura Finetek, Alphen aan den Rijn, The Netherlands)
and cryosectioned at 7 mm for histological and immunohisto-
chemical examinations. A central portion of the human graft was
placed in TEM fixative for ultrastructural imaging.
Immunostaining of bioengineered grafted tissue
Immunofluorescence staining was performed on frozen graft tissue
sections after 10-min fixation with ice-cold acetone and/or methanol
(7 mm thickness). Sections were blocked for 1 hour at room
temperature (RT) with 3% fetal bovine serum in phosphate buffered
saline before incubation with primary antibodies against hC7 LH7.2
(Sigma-Aldrich) in a 1:500 dilution (Supplementary Table S1 online),
desmoglein-1 (Fitzerald Industries, Acton, MA), involucrin (Sigma-
Aldrich), keratin 10 (in-house), complex IV subunit II MTCO2
(Abcam, Cambridge, UK) overnight at 4 C. Secondary antibody
incubation with Alexa Fluor goat antimouse 488 (Invitrogen, Paisley,
UK), goat antirabbit Cy3 (Life Technologies, Paisley, UK), and strep
488 was followed for 1 hour at RT. Sections were stained with 4’.6-
diamidino-2-phenylindole (5 mg/ml) and mounted using a ProLong
Gold antifade agent (Life Technologies). These were also stained by a
hematoxylin and eosin histochemical technique. Staining was
visualized and imaged using a Leica DMLB upright microscope
(Leica Microsystems CMS, Wetzlar, Germany) and a Zeiss Axiophot
2 (Zeiss, Oberkochen, Germany) and processed using Image-Pro 6.2
(MediaCybernetics, Rockville, MD). Confocal imaging was carried
out on a Zeiss LSM 510 Meta laser confocal microscope (Zeiss).
Postprocessing was carried out using ImageJ.
Preparation of skin grafts for TEM
For TEM, the central piece (approximately 3  3 mm2) of each skin
graft was dissected out and fixed with half strength Karnovsky’s
fixative (2% [v/v] paraformaldehyde, 2.5% [v/v] glutaraldehyde in
0.1 M phosphate buffer [pH 7.4]) for 3e5 hours at RT and kept at 4
C until further processing. After the initial fixation, tissue samples
were rinsed several times in phosphate buffer and postfixed with
1.3% osmium tetroxide in double distilled water for 2 hours at RT.
Samples were then washed, en bloc stained with 2% uranyl acetate
in 50% ethanol and dehydrated in a graded series of ethanols. Tissue
samples were further equilibrated with propylene oxide before
infiltration with TAAB epoxy resin, embedded, and polymerized at
70 C for 24 hours. Ultrathin sections (70e90 nm) were prepared
using a Reichert-Jung Ultracut E ultramicrotome (Eeichert-Jung,
Vienna, Austria), mounted on 150 mesh copper grids (Gilder,
Grantham, UK), contrasted using uranyl acetate and lead citrate and
examined on a FEI Tecnai 12 (FEI, Hillsboro, OR) transmission mi-
croscope operated at 120 kV. Images were acquired with an AMT
16000M camera (Advanced Microscopy Techniques, Woburn, MA).
Morphological examination and AF scoring of the TEM slides was
blinded and performed by an ultrastructural microscopy specialist.
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